Arthritis research & therapy · 2004
Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ponchel Frederique, Verburg Robert J, Bingham Sarah J, Brown Andrew K, Moore John, Protheroe Andrew, Short Kath, Lawson Catherine A, Morgan Ann W, Quinn Mark, Buch Maya, Field Sarah L, Maltby Sarah L, Masurel Aurelie, Douglas Susan H, Straszynski Liz, Fearon Ursula, Veale Douglas J, Patel Poulam, McGonagle Dennis, Snowden John, Markham Alexander F, Ma David, van Laar Jacob M, Papadaki Helen A, Emery Paul, Isaacs John D
Аннотация
We previously demonstrated prolonged, profound CD4+ T-lymphopenia in rheumatoid arthritis (RA) patients following lymphocyte-depleting therapy. Poor reconstitution could result either from reduced de novo T-cell production through the thymus or from poor peripheral expansion of residual T-cells. Interleukin-7 (IL-7) is known to stimulate the thymus to produce new T-cells and to allow circulating mature T-cells to expand, thereby playing a critical role in T-cell homeostasis. In the present study we demonstrated reduced levels of circulating IL-7 in a cross-section of RA patients. IL-7 production by bone marrow stromal cell cultures was also compromised in RA. To investigate whether such an IL-7 deficiency could account for the prolonged lymphopenia observed in RA following therapeutic lymphodepletion, we compared RA patients and patients with solid cancers treated with high-dose chemotherapy and autologous progenitor cell rescue. Chemotherapy rendered all patients similarly lymphopenic, but this was sustained in RA patients at 12 months, as compared with the reconstitution that occurred in cancer patients by 3-4 months. Both cohorts produced naive T-cells containing T-cell receptor excision circles. The main distinguishing feature between the groups was a failure to expand peripheral T-cells in RA, particularly memory cells during the first 3 months after treatment. Most importantly, there was no increase in serum IL-7 levels in RA, as compared with a fourfold rise in non-RA control individuals at the time of lymphopenia. Our data therefore suggest that RA patients are relatively IL-7 deficient and that this deficiency is likely to be an important contributing factor to poor early T-cell reconstitution in RA following therapeutic lymphodepletion. Furthermore, in RA patients with stable, well controlled disease, IL-7 levels were positively correlated with the T-cell receptor excision circle content of CD4+ T-cells, demonstrating a direct effect of IL-7 on thymic activity in this cohort.
Предметные рубрики MeSH
AlemtuzumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeoplasmArthritis, RheumatoidAutoimmune DiseasesBlood Specimen CollectionBone MarrowCD4-Positive T-LymphocytesCells, CulturedCohort StudiesCombined Modality TherapyCytokinesGene Rearrangement, T-LymphocyteHumansInterleukin-6Interleukin-7Lymphocyte DepletionLymphopeniaLymphopoiesisNeoplasmsOncostatin MPeripheral Blood Stem Cell TransplantationStromal CellsThymus GlandTransforming Growth Factor betaTumor Necrosis Factor-alpha